i-RNA Corporation

Profile

i-RNA Corporation is a preclinical biotech developing siRNA therapeutics for diabetic retinopathy, a leading cause of blindness. Its approach targets HOTAIR, a long non-coding RNA regulating disease-driving pathways, including angiogenesis, inflammation, and oxidative stress, and key proteins including VEGF, enabling broader disease-modifying potential beyond current standards of care. Its modified siRNA molecules have demonstrated robust preclinical efficacy, including a lead candidate designed for topical eye drop delivery, offering a safer, patient-friendly alternative to intravitreal anti-VEGF injections.

i-rna corporation

Website

i-rna.ca

Contact


Event details

Date: June 22 - 25, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

23 in total